01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

#HVO hVIVO PLC – Appointment of Independent Non-Executive Director May 29, 2025 – Posted in: Blog, hVIVO (HVO)

hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that further to its announcement on 12 May 2025, the Company has appointed Tracey James as Independent Non-Executive Director from 1 June 2025. Tracey will be Chair of the Audit Committee, and a member of the Remuneration and Nominations Committees. Tracey is a Chartered Accountant with 26 years’ experience working at Grant Thornton UK LLP…

Continue reading

#HVO hVIVO PLC – Annual Report, Notice of AGM & Directorate Change May 12, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, confirms that the Company’s Annual Report and Accounts for the year ended 31 December 2024 and the Notice of Annual General Meeting (“AGM”) will be posted to shareholders today.   The 2024 Annual Report and Accounts, the Notice of AGM and accompanying form of proxy are available to download from the Company’s website www.hvivo.com.   The Annual…

Continue reading

#HVO hVIVO PLC – Positive results from flu human challenge study April 3, 2023 – Posted in: hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, notes the announcement by Cidara Therapeutics, Inc. (“Cidara”), reporting positive interim results from an ongoing human challenge study testing CD388. hVIVO is conducting the Phase 2a single-center, randomised, double-blinded, placebo-controlled trial using its H3N2 Influenza Human Challenge Study Model.   CD388 is…

Continue reading